Classes I to IV and the three miscellaneous agents side by side: what each blocks, what it does to the action potential (read off the slide pictures), what it does to conduction, what it is for, what it causes and what to avoid.
| Class and drugs | What it blocks | Effect on the action potential | Main actions | Indications | Main adverse effects | Avoid, cautions and interactions | Source |
|---|---|---|---|---|---|---|---|
| Class IA quinidine, procainamide, disopyramide | Sodium channel (prefers the open channel; slow dissociation) | Slower, lower phase 0; longer action potential (slide 8 picture) | Slow conduction; prolong the action potential and refractory period; quinidine is also anticholinergic and an alpha blocker at higher doses | Supraventricular tachycardia; ventricular tachycardia; prevention of ventricular fibrillation and premature ventricular contractions | Torsades de pointes; quinidine: diarrhea (30 to 50 percent), cinchonism, thrombocytopenia, quinidine sudden death; procainamide: lupus-like syndrome, bone marrow suppression; disopyramide: antimuscarinic effects, heart failure | Disopyramide contraindicated in heart block and glaucoma; quinidine inhibits CYP2D6 (codeine, morphine) | L10 slide 8 slide 6 slide 11 slide 13 slide 15 |
| Class IB lidocaine | Sodium channel (prefers the inactivated channel; rapid dissociation); higher affinity in ischemic tissue, little effect in normal tissue | Shorter action potential (phase 3 shortened); phase 0 unchanged (slide 16 picture) | Shorten phase 3; decrease ectopic foci automaticity | Ventricular tachycardia and premature beats, ventricular fibrillation, acute myocardial infarction (Wolff-Parkinson-White is also listed); not effective against atrial arrhythmias | Central nervous system toxicity: drowsiness, confusion, restlessness, muscle twitches, seizures; nystagmus is the early sign; hypersensitivity | Intravenous only (extensive first-pass metabolism); contraindications: seizures, age | L10 slide 16 slide 17 slide 18 slide 19 |
| Class IC flecainide, propafenone | Sodium channel (prefers the open channel; very slow dissociation); flecainide also blocks potassium channels in the ventricles; propafenone also has beta-blocking activity | Markedly slower phase 0 (slide 20 picture) | Slow conduction; prolong the refractory period; affect the normal heart; flecainide prolongs the PR, QRS and QT intervals | Life-threatening ventricular tachycardia or fibrillation; refractory supraventricular tachycardia; flecainide prevents premature ventricular contractions | Increased mortality after myocardial infarction (flecainide); proarrhythmia (ventricular tachycardia resistant to treatment); bronchospasm; blurred vision; thrombocytopenia; propafenone: agranulocytosis, worsened heart failure | Flecainide only without significant structural heart damage; long half-life (14 hours) | L10 slide 20 slide 21 slide 22 slide 23 slide 24 |
| Class II propranolol (nonselective); metoprolol, acebutolol, esmolol (beta-1 selective) | Beta receptors | Flatter phase 4 in pacemaker cells, so the next beat comes later (slide 25 picture) | Slow conduction; decrease automaticity; prolong atrioventricular conduction; negative inotropic and chronotropic effects; propranolol is membrane stabilizing | Supraventricular arrhythmias; ventricular ectopic beats and myocardial infarction (propranolol); esmolol is the intravenous short-acting agent | Heart failure, heart block, hypotension, bronchospasm (less with beta-1 selective agents); sedation and fatigue | Asthma (use a beta-1 selective agent); digitalis toxicity with digoxin | L10 slide 25 slide 26 slide 28 slide 29 |
| Class III amiodarone, dofetilide, sotalol | Potassium channels (reduce potassium efflux); amiodarone also blocks inactivated sodium channels, calcium channels and alpha and beta receptors; sotalol is also a beta blocker | Longer action potential: phase 3 repolarization delayed; upstroke unchanged (slide 30 picture) | Prolong phase 3 repolarization, the refractory period and the action potential duration | Amiodarone: recurrent ventricular tachycardia or fibrillation resistant to other drugs, atrial fibrillation; intravenous for acute ventricular tachycardia or fibrillation. Dofetilide: normal rhythm in atrial fibrillation. Sotalol: atrial flutter and fibrillation, ventricular tachyarrhythmia | Amiodarone: pulmonary fibrosis, thyroid (hyper or hypo), blue-gray skin, corneal deposits, hepatic dysfunction. Dofetilide and sotalol: torsades de pointes; dofetilide marked QT prolongation; sotalol bronchospasm | Amiodarone: half-life about 40 days, loading doses; raises digoxin, warfarin, flecainide, phenytoin, procainamide. Dofetilide: special training; renal elimination | L10 slide 30 slide 31 slide 32 slide 33 slide 34 slide 35 |
| Class IV verapamil, diltiazem | L-type calcium channel (both activated and inactivated channels; most effective in the most active tissue) | Flatter phase 4 in pacemaker cells, as with class II (slide 37 picture) | Decrease automaticity; slow atrioventricular node conduction; suppress the sinoatrial node; negative inotropic | Paroxysmal supraventricular tachycardia; atrial fibrillation | Hypotension, edema | Avoid in ventricular arrhythmias, sick sinus syndrome, depressed cardiac function; caution in liver damage | L10 slide 37 slide 38 slide 39 |
| Adenosine miscellaneous | Activates potassium channels in the atria and blocks calcium channels | Hyperpolarizes cells | Decreases conduction velocity (may stop the heart for 2 to 3 seconds); decreases automaticity; prolongs the refractory period; half-life about 10 seconds | Paroxysmal supraventricular tachycardia (Wolff-Parkinson-White is also listed) | Flushing (20 percent), shortness of breath, burning in the chest | — | L10 slide 41 slide 42 |
| Digoxin digitalis; miscellaneous | Sodium-potassium ATPase inhibition; also listed: inhibits calcium channels in the atrioventricular node | — | Slows atrioventricular conduction; indirectly increases parasympathetic tone and decreases sympathetic tone; can induce heart block | Slow the ventricular rate; induce heart block in atrial flutter and fibrillation | Nausea, vomiting, diarrhea, anorexia; confusion, delirium, headache, seizures, visual disturbances | Avoid calcium channel blockers and beta blockers with it | L10 slide 43 slide 44 |
| Magnesium sulfate miscellaneous | — | — | — | Torsades de pointes (intravenous) | Bradycardia, flushing, headache, respiratory paralysis | — | L10 slide 45 |